Literature DB >> 3741249

Aqueous vs viscous phenylephrine. I. Systemic absorption and cardiovascular effects.

V Kumar, R D Schoenwald, W A Barcellos, D S Chien, J C Folk, T A Weingeist.   

Abstract

We studied 30 patients undergoing vitreoretinal surgery to compare the systemic absorption and cardiovascular effects of 2.5% aqueous and 2.5% viscous (21 cp) ophthalmic solutions of phenylephrine hydrochloride. No significant differences were noted in the plasma levels or changes in blood pressure between the two groups, although there was a tendency toward higher mean plasma levels and blood pressures in groups receiving 2.5% aqueous phenylephrine hydrochloride. Maximum plasma levels were achieved within the first 20 minutes following topical application of phenylephrine eye drops, irrespective of the nature of the vehicle. This finding emphasizes the importance of monitoring these patients, especially those at high risk for any adverse cardiovascular effects during the first 20 to 30 minutes following instillation of phenylephrine eye drops. The patients in our study were supine and under general anesthesia. Therefore, there was no effect by lid blinking, the lacrimal pump, or gravity, which would ordinarily increase absorption by the nasal mucosa through the nasolacrimal system. By eliminating these variable factors, such as lid blinking, the study was performed in a stable and controlled manner, but the results may not be directly applicable to an upright awake patient.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741249     DOI: 10.1001/archopht.1986.01050200095058

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  5 in total

Review 1.  Ocular drug delivery. Pharmacokinetic considerations.

Authors:  R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

2.  Ocular phenylephrine 2.5% continues to be dangerous.

Authors:  Nauman Ahmed; Waleed Riad; Abdullah Altorpaq; Abdul Zahoor
Journal:  BMJ Case Rep       Date:  2009-03-02

Review 3.  Non-prescription sympathomimetic agents and hypertension.

Authors:  S S Chua; S I Benrimoj
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

Review 4.  Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.

Authors:  Y W Lam; A M Shepherd
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

5.  Bronchoconstriction following instillation of phenylephrine eye drops in premature infants with bronchopulmonary dysplasia: two cases report.

Authors:  Hyun Jee Kim; Jin Guk Choi; Kyung-Hwa Kwak
Journal:  Korean J Anesthesiol       Date:  2015-11-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.